Microfluidic Strategy for Circulating Tumour Cells Analysis in Cancer Patients

用于癌症患者循环肿瘤细胞分析的微流体策略

• 批准号: nhmrc : 1088966
• 金额: $ 28.62万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/microfluidic-strategy-circulating-cancer-patients/519241
• 关键词: Microfluidic; Strategy; Circulating; Tumour; Cells

My approach and ultimate goal over the next 4 years is to demonstrate the use of recently discovered “Nanoshearing” technology as a standard diagnostic tool for cancer patients undergoing systemic therapy and assess the impact of standard protocols in predicting response to therapy and patient outcomes. Data from this study could potentially define new standards of clinical practice, as they relate to follow-up screening for response to therapy and recurrence of disease.

我在未来4年的方法和最终目标是证明使用最近发现的“纳米剪切”技术作为接受系统治疗的癌症患者的标准诊断工具，并评估标准方案在预测治疗反应和患者结局方面的影响。这项研究的数据可能会定义新的临床实践标准，因为它们与治疗反应和疾病复发的随访筛查有关。